About BiondVax Pharmaceuticals (NASDAQ:BVXV)
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. Its technology utilizes a combination of conserved epitomes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect. The Company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.97 per share
Price / Book3.05
Return on Equity-109.95%
Return on Assets-78.04%
Frequently Asked Questions for BiondVax Pharmaceuticals (NASDAQ:BVXV)
What is BiondVax Pharmaceuticals' stock symbol?
BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."
When will BiondVax Pharmaceuticals make its next earnings announcement?
Who are some of BiondVax Pharmaceuticals' key competitors?
Some companies that are related to BiondVax Pharmaceuticals include Brainstorm Cell Therapeutics (BCLI), NovaBay Pharmaceuticals (NBY), Senomyx (SNMX), Vernalis plc (VER), Tissue Regenix Group PLC (TRX), Navidea Biopharmaceuticals (NAVB), Abzena PLC (ABZA), CytRx Corporation (CYTR), ReNeuron Group plc (RENE), Aptose Biosciences (APTO), OvaScience (OVAS), OncoSec Medical Incorporated (ONCS), Ohr Pharmaceuticals (OHRP), Prima BioMed Ltd (PBMD), AEterna Zentaris (AEZS), Bio-Path Holdings (BPTH), Scancell Holdings Plc (SCLP) and Oncobiologics (ONS).
Who are BiondVax Pharmaceuticals' key executives?
BiondVax Pharmaceuticals' management team includes the folowing people:
- Avner Rotman, Chairman of the Board (Age 74)
- Ron Babecoff, Chief Executive Officer, President, Director (Age 54)
- Uri Ben-Or, Chief Financial Officer (Age 47)
- Tamar Ben-Yedidia, Chief Scientific Officer (Age 53)
- Yisrael Gewirtz, Internal Auditor (Age 40)
- George H. Lowell, Director (Age 72)
- Ori Mor, Director (Age 46)
- Jack Rosen, Director (Age 71)
- Irit Ben-Ami, External Director (Age 56)
- Ruth Ben Yakar, Independent Director (Age 47)
When did BiondVax Pharmaceuticals IPO?
(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.
Who owns BiondVax Pharmaceuticals stock?
How do I buy BiondVax Pharmaceuticals stock?
Shares of BiondVax Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BiondVax Pharmaceuticals' stock price today?
One share of BiondVax Pharmaceuticals stock can currently be purchased for approximately $6.00.
How big of a company is BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals has a market capitalization of $39.28 million. The company earns $-2,380,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. BiondVax Pharmaceuticals employs 14 workers across the globe.
How can I contact BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals' mailing address is 14 Einstein Street, Nes Ziona L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]
MarketBeat Community Rating for BiondVax Pharmaceuticals (BVXV)MarketBeat's community ratings are surveys of what our community members think about BiondVax Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for BiondVax Pharmaceuticals (NASDAQ:BVXV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for BiondVax Pharmaceuticals (NASDAQ:BVXV)
Analysts' Ratings History for BiondVax Pharmaceuticals (NASDAQ:BVXV)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
Earnings History for BiondVax Pharmaceuticals (NASDAQ:BVXV)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for BiondVax Pharmaceuticals (NASDAQ:BVXV)
2017 EPS Consensus Estimate: ($0.01)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for BiondVax Pharmaceuticals (NASDAQ:BVXV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for BiondVax Pharmaceuticals (NASDAQ BVXV)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for BiondVax Pharmaceuticals (NASDAQ BVXV)
Financials are not available for this stock.
BiondVax Pharmaceuticals (NASDAQ BVXV) Chart for Thursday, November, 23, 2017